Effects of the combined use of benazepril and valsartan on apoptosis in the kidney of rats with adriamycin-induced nephritic glomerulosclerosis

Abstract

The effects of the combined use of angiotensin converting enzyme inhibitor (ACEI) benazepril and angiotensin II type 1 receptor antagonist (AT1RA) valsartan on apoptosis and the expression of apoptosis-related proteins Fas and FasL in the kidney of rats with adriamycin-induced nephritic glomerulosclerosis was investigated. Uninephrectomy and the injection of adriamycin induced the rat model of glomerulosclerosis. Benazepril (6 mg/kg), valsantan (20 mg/kg), or benazepril (3 mg/kg) plus valsantan (20 mg/kg) was respectively delivered daily by gavage to the rats in three treatment groups for 12 weeks. Apoptosis was examined by means of terminal-deoxynucleotidyl transferase mediated d-UTP nick end labeling (TUNEL). Immunohistochemistry was adopted to detect the expression of Fas and FasL. Software of pathological analysis quantitated the levels of Fas and FasL. The results showed that as compared with those in the control group, the kidneys in the model group had more severe glomerulosclerosis, much more apoptotic cells and higher levels of expression of Fas and FasL. The degree of glomerulosclerosis, the number of apoptotic cells and the levels of expression of Fas and FasL were reduced by benazepril and valsartan. The combined use of benazepril and valsartan had the best therapeutic effect. It was concluded that benazepril and valsartan could suppress the excessive apoptosis of kidney cells by lowering the expression of the apoptosis-related proteins Fas and FasL, so as to postpone the process of glomerulosclerosis. The combined use of benazepril and valsartan has better therapeutic effect.

Keywords

benazepril / valsartan / adriamycin nephropathy / apoptosis / Fas / FasL

References

[1] RaijL, AzarS, KeaneW. Mesangial immune injury, hypertension and progressive glomerular damage in Dahl rats. Kidney Int, 1984, 26(2): 137-137

[2] YingB, JohnsonT S, ThomasG, et al. . Expression of apoptosis-related genes and proteins in experimental chronic renal scarring. J Am Soc Nephrol, 2001, 12(2): 275-275

[3] AizawaT, IshizakaN, KurokawaK, et al. . Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int, 2001, 59(2): 645-645

[4] DingG, ReddyK, KapasiA A, et al. . Angiotensin II induces apoptosis in rat glomerular epithelial cell. Am J Physiol Renal Physiol, 2002, 283(1): 173-173

[5] OzenS, UstaY, Sahin-ErdemliI, et al. . Association of nitric oxide production and apoptosis in a model of experimental nephropathy. Nephrol Dial Transplant, 2001, 16(1): 32-32

[6] KitamuraH, ShimizuA, MasudaY, et al. . Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model. Exp Nephrol, 1998, 6(4): 328-328

[7] SudaT, TakahashiR, GolsteinG, et al. . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 1993, 75(6): 1169-1169

[8] KellyD J, CoxA J, TolcosM, et al. . Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int, 2002, 61(1): 31-31

[9] CaoZ, CooperM E. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol, 2001, 21(6): 554-554

[10] WangW, TzanidisA, DivjakM, et al. . Altered signaling and regulatory mechanisms of apoptosis in focal and segmental glomerulosclerosis. J Am Soc Nephrol, 2001, 12(7): 1422-1422

[11] OnoH, OnoY, TakanohashiA, et al. . Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension, 2001, 38(12): 1300-1300

[12] NakaoN, YoshimuraA, MoritaH, et al. . Combination treatment of angiotensin II receptor blocker and angitensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet, 2003, 361(9352): 117-117